231 related articles for article (PubMed ID: 18239399)
1. Mild-to-moderate active luminal Crohn's disease.
Michetti P; Juillerat P; Mottet C; Pittet V; Gonvers JJ; Vader JP; Froehlich F; Felley C
Digestion; 2007; 76(2):92-8. PubMed ID: 18239399
[TBL] [Abstract][Full Text] [Related]
2. Therapy of mild to moderate luminal Crohn's disease.
Michetti P; Juillerat P; Mottet C; Gonvers JJ; Burnand B; Vader JP; Froehlich F; Felley C
Digestion; 2005; 71(1):13-8. PubMed ID: 15711043
[TBL] [Abstract][Full Text] [Related]
3. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
4. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
5. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
6. Review article: chronic active disease and maintaining remission in Crohn's disease.
Kamm MA
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
8. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
9. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
[No Abstract] [Full Text] [Related]
10. Management of Crohn's disease--a practical approach.
Knutson D; Greenberg G; Cronau H
Am Fam Physician; 2003 Aug; 68(4):707-14. PubMed ID: 12952387
[TBL] [Abstract][Full Text] [Related]
11. Severe exudative ascites as an initial presentation of Crohn's disease.
Tekin F; Vatansever S; Ozütemiz O; Musoğlu A; Ilter T
Turk J Gastroenterol; 2005 Sep; 16(3):171-3. PubMed ID: 16245232
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chronic inflammatory bowel diseases].
Lémann M
Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.
Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D
Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832
[TBL] [Abstract][Full Text] [Related]
15. Drug safety in Crohn's disease therapy.
Juillerat P; Pittet V; Felley C; Mottet C; Froehlich F; Vader JP; Gonvers JJ; Michetti P
Digestion; 2007; 76(2):161-8. PubMed ID: 18239408
[TBL] [Abstract][Full Text] [Related]
16. [Medical therapy of inflammatory bowel diseases: Crohn's disease].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(24):1107-14. PubMed ID: 17561480
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacologic therapy of Crohn's disease and ulcerative colitis].
Banai J
Orv Hetil; 2000 May; 141(22):1171-7. PubMed ID: 10853345
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Crohn's disease.
Hoffmann JC; Zeitz M
Hepatogastroenterology; 2000; 47(31):90-100. PubMed ID: 10690589
[TBL] [Abstract][Full Text] [Related]
19. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
Feagan BG
Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
[No Abstract] [Full Text] [Related]
20. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Plamondon S; Ng SC; Kamm MA
Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
